ReviewFrontiers in neuroscience2026
PANoptosis in neurological disorders: from inflammatory cell death mechanisms to neuroprotective strategies.
Review in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PANoptosis is now regarded as an inflammatory form of programmed cell death (PCD). It reflects the coordinated involvement of apoptosis, pyroptosis, and necroptosis, usually through the PANoptosome in a shared pathological environment. This concept may be especially useful in neurological diseases. It helps explain why neuronal death, sustained inflammatory activation, and tissue injury often develop together and reinforce one another. Neural tissue is particularly sensitive to oxidative stress, mitochondrial dysfunction, immune-mediated inflammation, and blood-brain barrier disruption. These pathological changes are common in many forms of neural injury. Therefore, abnormal PANoptosis activation may provide a common mechanism linking different types of nervous system damage. This review summarizes the historical evolution, molecular mechanisms, disease-related roles, and intervention strategies of PANoptosis in neurological disorders. It focuses on PANoptosome assembly and key mechanistic nodes, including NOD-like receptor family pyrin domain-containing 3 (NLRP3), caspase-8, the receptor-interacting serine/threonine protein kinase 1 (RIPK1)/receptor-interacting serine/threonine protein kinase 3 (RIPK3)/mixed lineage kinase domain-like protein (MLKL) axis, gasdermin D (GSDMD), and Ninjurin 1 (NINJ1). It also highlights current translational limitations, such as disease heterogeneity, incomplete cell-specific validation, and insufficient clinical evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.